OncoMethylome Sciences Signs Commercial Agreement with Laboratory Corporation of America for Colorectal Cancer Testing
"We are happy to make our methylation technology available to LabCorp for stool-based colorectal cancer testing. LabCorp's broad presence in North America and its leadership role in bringing novel screening services to the market, make it an attractive partner for OncoMethylome. Colorectal cancer can be treated effectively if diagnosed early; therefore, making our technology widely available for colorectal cancer screening purposes is of utmost importance" commented Herman Spolders, CEO of OncoMethylome.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.